Zevra Therapeutics, Inc. Operating Expenses
Zevra Therapeutics, Inc. (ZVRA) reported Operating Expenses of $7.79 million for the 3-month period ending 2019-06-30, per its 10-Q filed 2019-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2019-08-13
- Zevra Therapeutics, Inc. operating expenses for the quarter ending 2019-06-30 was $7.79M, a 43.97% decline year-over-year.
- Zevra Therapeutics, Inc. operating expenses for the quarter ending 2019-03-31 was $11.37M, a 23.02% decline year-over-year.
- Zevra Therapeutics, Inc. operating expenses for the quarter ending 2018-12-31 was $9.27M, a 13.72% increase year-over-year.
- Zevra Therapeutics, Inc. operating expenses for the quarter ending 2018-09-30 was $17.96M, a 86.83% increase year-over-year.
- Zevra Therapeutics, Inc. operating expenses for fiscal 2018 was $55.90M, a 67.54% increase from fiscal 2017.
- Zevra Therapeutics, Inc. operating expenses for fiscal 2017 was $33.37M, a 10.98% decline from fiscal 2016.
- Zevra Therapeutics, Inc. operating expenses for fiscal 2016 was $37.48M, a 64.29% increase from fiscal 2015.
- Zevra Therapeutics, Inc. operating expenses for fiscal 2015 was $22.81M, a 38.75% increase from fiscal 2014.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2019-06-30 | $7.79M 10-Q · filed 2019-08-13 | $19.16M 10-Q · filed 2019-08-13 | $28.43M derived: sum of 3 quarters · filed 2019-08-13 | $46.39M derived: sum of 4 quarters · filed 2019-08-13 |
| 2019-03-31 | $11.37M 10-Q · filed 2019-05-14 | $20.64M derived: sum of 2 quarters · filed 2019-05-14 | $38.59M derived: sum of 3 quarters · filed 2019-05-14 | $52.50M derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-12-31 | $9.27M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $27.23M derived: sum of 2 quarters · filed 2019-03-01 | $41.13M derived: sum of 3 quarters · filed 2019-08-13 | $55.90M 10-K · filed 2019-03-01 |
| 2018-09-30 | $17.96M 10-Q · filed 2018-11-09 | $31.87M derived: sum of 2 quarters · filed 2019-08-13 | $46.63M 10-Q · filed 2018-11-09 | $54.78M derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-06-30 | $13.91M 10-Q · filed 2019-08-13 | $28.68M 10-Q · filed 2019-08-13 | $36.83M derived: sum of 3 quarters · filed 2019-08-13 | $46.44M derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-03-31 | $14.77M 10-Q · filed 2019-05-14 | $22.92M derived: sum of 2 quarters · filed 2019-05-14 | $32.53M derived: sum of 3 quarters · filed 2019-05-14 | $40.76M derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | $8.15M 10-K · filed 2018-03-30 | $17.76M derived: sum of 2 quarters · filed 2018-11-09 | $25.99M derived: sum of 3 quarters · filed 2018-11-09 | $33.37M 10-K · filed 2019-03-01 |
| 2017-09-30 | $9.61M 10-Q · filed 2018-11-09 | $17.84M derived: sum of 2 quarters · filed 2018-11-09 | $25.22M 10-Q · filed 2018-11-09 | $36.05M derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | $8.22M 10-Q · filed 2018-08-10 | $15.60M 10-Q · filed 2018-08-10 | $26.44M derived: sum of 3 quarters · filed 2018-08-10 | $36.84M derived: sum of 4 quarters · filed 2018-08-10 |
| 2017-03-31 | $7.38M 10-Q · filed 2018-05-11 | $18.22M derived: sum of 2 quarters · filed 2018-05-11 | $28.62M derived: sum of 3 quarters · filed 2018-05-11 | $37.89M derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | $10.84M 10-K · filed 2018-03-30 | $21.24M derived: sum of 2 quarters · filed 2018-03-30 | $30.51M derived: sum of 3 quarters · filed 2018-03-30 | $37.48M 10-K · filed 2018-03-30 |
| 2016-09-30 | $10.40M 10-K · filed 2018-03-30 | $19.68M derived: sum of 2 quarters · filed 2018-03-30 | $26.65M 10-Q · filed 2017-11-09 | $33.93M derived: sum of 4 quarters · filed 2018-03-30 |
| 2016-06-30 | $9.28M 10-K · filed 2018-03-30 | $16.25M 10-Q · filed 2017-08-10 | $23.53M derived: sum of 3 quarters · filed 2018-03-30 | $30.01M derived: sum of 4 quarters · filed 2018-03-30 |
| 2016-03-31 | $6.97M 10-K · filed 2018-03-30 | $14.25M derived: sum of 2 quarters · filed 2018-03-30 | $20.73M derived: sum of 3 quarters · filed 2018-03-30 | $26.69M derived: sum of 4 quarters · filed 2018-03-30 |
| 2015-12-31 | $7.28M 10-K · filed 2017-03-10 | $13.76M derived: sum of 2 quarters · filed 2017-03-10 | $19.72M derived: sum of 3 quarters · filed 2017-03-10 | $22.81M 10-K · filed 2018-03-30 |
| 2015-09-30 | $6.48M 10-K · filed 2017-03-10 | $12.44M derived: sum of 2 quarters · filed 2017-03-10 | $15.53M 10-Q · filed 2016-11-10 | $23.02M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | $5.96M 10-K · filed 2017-03-10 | $9.05M 10-Q · filed 2016-08-11 | $16.54M derived: sum of 3 quarters · filed 2017-03-10 | $20.88M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | $3.10M 10-K · filed 2017-03-10 | $10.58M derived: sum of 2 quarters · filed 2017-03-10 | $14.92M derived: sum of 3 quarters · filed 2017-03-10 | $17.97M derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | $7.49M 10-K · filed 2016-03-16 | $11.83M derived: sum of 2 quarters · filed 2016-03-16 | $14.87M derived: sum of 3 quarters · filed 2016-03-16 | $16.44M 10-K · filed 2017-03-10 |
| 2014-09-30 | $4.34M 10-K · filed 2016-03-16 | $7.38M derived: sum of 2 quarters · filed 2016-03-16 | $8.96M 10-Q · filed 2015-11-13 | |
| 2014-06-30 | $3.04M 10-K · filed 2016-03-16 | $4.62M 10-Q · filed 2015-08-14 | ||
| 2014-03-31 | $1.57M 10-K · filed 2016-03-16 | |||
| 2013-12-31 | $4.72M 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |